These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 29930098

  • 21. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
    Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JS.
    Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
    Sarraf D, London NJ, Khurana RN, Dugel PU, Gune S, Hill L, Tuomi L.
    Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
    [Abstract] [Full Text] [Related]

  • 24. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD.
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [Abstract] [Full Text] [Related]

  • 25. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.
    Dugel PU, Petrarca R, Bennett M, Barak A, Weinberger D, Nau J, Jackson TL.
    Ophthalmology; 2012 Jul; 119(7):1425-31. PubMed ID: 22465819
    [Abstract] [Full Text] [Related]

  • 26. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).
    Bhisitkul RB, Desai SJ, Boyer DS, Sadda SR, Zhang K.
    Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339
    [Abstract] [Full Text] [Related]

  • 27. Recurrence Rate of Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration Managed with a Treat-Extend-Stop Protocol.
    Adrean SD, Chaili S, Grant S, Pirouz A.
    Ophthalmol Retina; 2018 Mar; 2(3):225-230. PubMed ID: 31047590
    [Abstract] [Full Text] [Related]

  • 28. Optical coherence tomography angiography of type 3 neovascularisation in age-related macular degeneration after antiangiogenic therapy.
    Phasukkijwatana N, Tan ACS, Chen X, Freund KB, Sarraf D.
    Br J Ophthalmol; 2017 May; 101(5):597-602. PubMed ID: 27503396
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group.
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [Abstract] [Full Text] [Related]

  • 31. [Wet form age-related macular degeneration two years treatment results using anti VEGF drugs].
    Studnička J, Rencová E, Dusová J, Marák J, Burova M, Rozsíval P, Jarkovský J, Kandrnal V.
    Cesk Slov Oftalmol; 2013 Aug; 69(3):96-101. PubMed ID: 24437955
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
    Abdin AD, Suffo S, Asi F, Langenbucher A, Seitz B.
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
    [Abstract] [Full Text] [Related]

  • 35. Morphologic features of large choroidal vessel layer: age-related macular degeneration, polypoidal choroidal vasculopathy, and central serous chorioretinopathy.
    Baek J, Lee JH, Jung BJ, Kook L, Lee WK.
    Graefes Arch Clin Exp Ophthalmol; 2018 Dec; 256(12):2309-2317. PubMed ID: 30259090
    [Abstract] [Full Text] [Related]

  • 36. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC, Suñer IJ, Hammer ME, Grizzard WS.
    Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
    Kvannli L, Krohn J.
    Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
    [Abstract] [Full Text] [Related]

  • 39. Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration.
    Kumar N, Mrejen S, Fung AT, Marsiglia M, Loh BK, Spaide RF.
    Ophthalmology; 2013 Feb; 120(2):334-41. PubMed ID: 23137630
    [Abstract] [Full Text] [Related]

  • 40. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
    Arnold JJ, Markey CM, Kurstjens NP, Guymer RH.
    BMC Ophthalmol; 2016 Mar 24; 16():31. PubMed ID: 27009515
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.